Presentation is loading. Please wait.

Presentation is loading. Please wait.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,

Similar presentations


Presentation on theme: "Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,"— Presentation transcript:

1 Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD, Daniel B. Costa, MD, PhD, Deepa Rangachari, MD  Journal of Thoracic Oncology  Volume 12, Issue 4, Pages e35-e36 (April 2017) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Radiographic response and progression of disease over time: baseline disease at diagnosis of metastasis (A), response to first-line erlotinib (B), disease progression during erlotinib therapy (C), and response to second-line osimertinib (D). Journal of Thoracic Oncology  , e35-e36DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,"

Similar presentations


Ads by Google